Verified Document

Pharmacutical Industry What Do You Think The Term Paper

Pharmacutical Industry What do you think the pharmaceutical Industry will look like in 10 years? Why?

What do you think the pharmaceutical industry will look like in ten years? Why?

Despite the sharp upturn in profits over the past twenty years for the pharmaceutical industry, there is grave concern amongst industry insiders that this cannot continue indefinitely. "Increasing price and cost pressure, regulatory changes and expiring patents are leading to shrinking margins in the pharmaceutical industry. Almost three in four companies believe their industry is in a strategic crisis" (Berger 2013). This is despite the fact that "the top 10 pharmaceutical companies were able to increase sales by about 13% between 2009 and 2010" (Berger 2013). Concerns abound that the failure to create a new 'hot' drug will create substantial downward price pressure. "R&D costs have risen by more than 80% worldwide over the past 10 years. On the other hand, the number of new product launches has dropped by 43%. Therefore, almost half of the companies surveyed believe that the Return on Investment (ROI) in the area of R&D is more or less negative" (Berger 2013).

One potential area of growth is the developing world: emerging markets are expected to increase in size about 12%. By 2016, especially in China, Brazil, India and Russia, "emerging markets will account for nearly 40% of the global market for pharma solutions by 2016 (Berger 2013). However, this cannot abate concerns about the rash of drugs that are facing what is known as the 'patent cliff' -- "40 brand-name drugs -- valued at $35 billion in annual sales -- lost their patent protection,...

Parts of this document are hidden

View Full Document
svg-one

Not only are these drugs more attractive to consumers because of their low cost -- in many instances, insurance companies will not pay for non-generic drugs if the cheaper generic version is considered to be pharmaceutically equivalent to the non-generic. Pharmaceutical companies will suffer a profound financial blow if they cannot create new non-generic drugs that are equally demand as these former warhorses that drew in such revenue to their coffers.
However, there are some 'hopeful' signs, not necessarily hopeful in terms of what they suggest for human health, but hopeful in the sense that they are likely to be sources of profit for pharmaceutical companies within the next coming decades. The rise in obesity and chronic conditions associated with obesity such as type II diabetes is also expected to be a major growth area for 'big pharma.' Today, the worldwide estimate of persons with diabetes is 177 million, according to the World Health Organization, with an expected increase to 300 million by 2025 (Diabetes, 2013, WHO). "The oral diabetes market could be worth more than $18 billion by 2020" (Carroll 2013). There is particular interest in growing the market for diabetes drugs administered by mouth (versus injection such as insulin) and treatments for early stage or pre-diabetes (Carroll 2013).

In terms of the most lucrative products for diabetes: "insulin, test strips, glucose monitors and anti-diabetic drugs" lead the…

Cite this Document:
Copy Bibliography Citation

Related Documents

Pharmaceutical Industry the Purpose of
Words: 2330 Length: 9 Document Type: Term Paper

This relationship has an effect on the payment rates that CMS sets. Higher cost pharmaceutical therapies are systematically reimbursed below acquisition cost (i.e., the payment system is biased against full reimbursement for higher cost therapies). Reimbursement compared to acquisition cost for the top IO pharmaceuticals by total expenditures indicates that 9 of the 10 are significantly under reimbursed." Clinical Trials Report: Congress established Medicare beneficiaries numbering 40 million with a prescription

Pharmaceutical Industries: Merck & Co.,
Words: 959 Length: 3 Document Type: Term Paper

38 per share on the company's common stock for the first quarter of 2005. The dividend is payable January 3, 2005 to stockholders of records at the close of business on December 3, 2004. Growth in the ZETIA and VYTORIN franchises are expected to continue. T There are currently several candidates in Phase III that Merck plans to file in 2005 as well as Type 2 diabetes treatment and three vaccines.

Pharmaceuticals Industry Political and Social
Words: 1647 Length: 5 Document Type: Term Paper

There are two constant irritations in U.S. pharma companies' relationships internationally: Some developing nations, such as India, Brazil and South Africa, are chipping away at the patent situation, trying to shorten the time until the drugs can be brought out in generic form. The U.S. has supported high prices as the cost for innovation. Since other countries are not playing along, this means that their citizens are benefiting from the innovation paid

Pharmaceutical Industry How Does the
Words: 1497 Length: 5 Document Type: Term Paper

For example, before its paten ran out, "the price of Schering-Plough's top-selling allergy pill, Claritin, was raised thirteen times over fives years, for a cumulative increase of more than 50%, over four times the rate of general inflation." In 2002, the average price of the fifty drugs most used by senior citizens was approximately $1,500 for a year's supply, and although this refers to what the companies call the

Pharmaceutical Industry and Sec
Words: 2811 Length: 8 Document Type: Research Paper

McKesson Corporation (Mckesson) is an American pharmaceutical distributor with operations mainly in the U.S. The firm has been in operation since 1833, and boasts extensive market share, robust financial strength, and strong market power. The firm has built strong relationships with its key stakeholders, which adds to its strengths. Nonetheless, limited diversification and market focus as well as the threats of competition, unfavourable regulatory changes, and counterfeits present significant concerns

Pharmaceutical Industry and Society
Words: 954 Length: 3 Document Type: Research Proposal

Sustainability in Pharmaceuticals Industry Ethical Pricing in the Pharmaceutical Industry The reality of medicine if the modern era is that resources must be allocated to help support the development of new pharmaceutical and in turn, there must also be a way to compensate those who devote their resources to help cure some of the preventable diseases that plague the modern age. The moral issue at stake here is distributive justice, and Rawls'

Sign Up for Unlimited Study Help

Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.

Get Started Now